Aaron Novikoff

Another GLP-1R agonist is nothing new, but the first phase 3-trialed small molecule GLP-1R agonist has shown potential to change the landscape of treatment, combinatorial potential, and equitable accessibility. Want to know more? Below is our view! authors.elsevier.com/c/1mG3e9UKeTpc…

hello there the jacobian conjecture is false thanx to my close friend akhil for asking about it and my other close friend fable for working during the world cup final ((1+xy)^3 z + y^2 (1+xy) (4+3xy), y + 3 x (1+xy)^2 z + 3 x y^2 (4+3xy), 2 x - 3 x^2 y - x^3 z): \C^3\to \C^3, has jacobian determinant -2, and sends (0, 0, -1/4), (1, -3/2, 13/2), and (-1, 3/2, 13/2) to (-1/4, 0, 0)

Wild seeing Spain play in Texas!

This intro for Joey Chestnut 😮‍💨🌭 World record loading?

🚨 This guy is becoming the unofficial soundtrack of the World Cup. 🇩🇪 Every time he starts playing... Thousands join in. This isn't just football. It's a festival with a soundtrack. 🎷🔥 #FifaWorldCup #Germany vs #Ecuador

@AdamSchefter That’s extremely metaphoric for the team-friendly 4 year contract Jalen signed

This play will be replayed for years.

There’s an eagle flying around the stadium

Our Review on the evolving landscape of obesity pharmacotherapy is now online in @NatRevDrugDisc nature.com/articles/s4157… @TimoMueller_IDO @OdgaardJonas @JohansenVBI

An incredible honor, humbling to be recognized in a field filled with giants.

🏆 Congrats to Dr. @AaronNovikoff on being selected for the EASD Rising Star Symposium & #EFSD Rising Star Fellowship award for his lecture: Elucidating Novel Strategies for Precision Incretin #Pharmacology. We look forward to your #EASD2026 Lecture! Supported by @novonordisk

@bioinvestor24 It's in the slide deck as Berobenatide. They also list it as a "biologic" So now not just Lilly making that claim...

@RevathiSekar14 Thank you very much Revathi!

@AaronNovikoff Congrats Aaron!

Hi guys, our new paper is out! The GLP1–GIP–PPARα/γ/δ quintuple agonist, a novel strategy synergizing polypharmacology with specificity. Below is a hopeful explainer to avoid confusion. Give it a share. Not paid by twitter doing it for the love of the game nature.com/articles/s4158…

@IsmaelGlezGcia @TimoMueller_IDO Thanks Isma! Much appreciated. Hope all is good with you!

@AaronNovikoff Outstanding work!!!😱Congrats @AaronNovikoff @TimoMueller_IDO and all the team! You rock!

@AppleHelix This story leverages more the dual GPCR targeting for the sake of small molecule delivery rather than biased agonism, but I'm sure its a component (both GLP-1/GIP and conjugate in the study have the same pharmacodynamic profile at respective receptors)

@AaronNovikoff But how does it tell the story of minimizing beta arrestin recruitment, which my understanding is to Not have internalization.

Cool work by @AaronNovikoff and colleagues. Peptide drug conjugate??

Lastly, how is this possible? This type of research is impossible without the brilliant minds and efforts of both @TimoMueller_IDO and Daniela Liskiewicz, it simply could not have been done without them. Generational talents. To them, and to all our collaborators – thank you!

Want to know something cool? Delivery of Lani into only GLP1R+ cells (GLP1-Lani, black open circle) requires only GIPR coactivation (not Lani delivery, open red circle) to hit maximal BW loss, but Lani into GIPR+ cells is critical for superior glycemic control. You need both!